Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer

Biomaterials

Volumn 35, Issue 23, 2014, Pages 6118-6129

  Lv, Shixian ^a,d   Tang, Zhaohui ^a   Li, Mingqiang ^a,d   Lin, Jian ^a,d   Song, Wantong ^a   Liu, Huaiyu ^c   Huang, Yubin ^a   Zhang, Yuanyuan ^b   Chen, Xuesi ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c JILIN UNIVERSITY   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Chemotherapy; Controlled drug release; Drug co delivery; Nanoparticle; Polypeptide

Indexed keywords

AMINO ACIDS; CELL CULTURE; CELL DEATH; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; COPOLYMERS; DRUG INTERACTIONS; DRUG PRODUCTS; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; POLYPEPTIDES; TUMORS;

AMPHIPHILIC CO-POLYMERS; ANTICANCER TREATMENT; CANCER CELL APOPTOSIS; CO DELIVERIES; CONTROLLED DRUG RELEASE; HUMAN LUNG ADENOCARCINOMA CELLS; METHOXYPOLYETHYLENE GLYCOL; NON SMALL CELL LUNG CANCER;

LOADING;

COPOLYMER; DEOXYCHOLIC ACID; DOXORUBICIN; MACROGOL; NANOPARTICLE; PACLITAXEL; POLYGLUTAMIC ACID; POLYLYSINE; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; DRUG VEHICLE; MACROGOL DERIVATIVE; NANOCAPSULE; NANOCOMPOSITE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS; TUMOR VOLUME; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; DELAYED RELEASE FORMULATION; DIFFUSION; LUNG NEOPLASMS; NUDE MOUSE; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DELAYED-ACTION PREPARATIONS; DIFFUSION; DOXORUBICIN; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, NUDE; NANOCAPSULES; NANOCOMPOSITES; PACLITAXEL; PEPTIDES; PHARMACEUTICAL VEHICLES; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 84899995755     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.034     Document Type: Article

References (32)

1. Duan X.P., Xiao J.S., Yin Q., Zhang Z.W., Yu H.J., Mao S.R., et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 2013, 7:5858-5869.
2. Wang H., Zhao Y., Wu Y., Hu Y.L., Nan K.H., Nie G.J., et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 2011, 32:8281-8290.
3. Moulder S.L., Symmans W.F., Booser D.J., Madden T.L., Lipsanen C., Yuan L., et al. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res 2008, 14:7909-7916.
4. Han M., Lv Q., Tang X.J., Hu Y.L., Xu D.H., Li F.Z., et al. Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel siRNA polyamidoamine-hyaluronic acid complex. JControl Release 2012, 163:136-144.
5. von Minckwitz G., Raab G., Caputo A., Schutte M., Hilfrich F., Blohmer J.U., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. JClin Oncol 2005, 23:2676-2685.
6. Hu C.-M.J., Aryal S., Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv 2010, 1:323-334.
7. Zhao Y., Alakhova D.Y., Kabanov A.V. Can nanomedicines kill cancer stem cells?. Adv Drug Deliv Rev 2013, 65:1763-1783.
8. Wagner E. Programmed drug delivery: nanosystems for tumor targeting. Expert Opin Biol Ther 2007, 7:587-593.
9. Kim S., Shi Y., Kim J.Y., Park K., Cheng J.-X. Overcoming the barriers in micellar drug delivery: loading efficiency, invivo stability, and micelle-cell interaction. Expert Opin Drug Deliv 2010, 7:49-62.
10. Peer D., Karp J.M., Hong S., FaroKHzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
11. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. JClin Oncol 2005, 23:7794-7803.
12. Barenholz Y. Doxil (R) - the first FDA-approved nano-drug: lessons learned. JControl Release 2012, 160:117-134.
13. Lim W.T., Tan E.H., Toh C.K., Hee S.W., Leong S.S., Ang P.C.S., et al. Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol (R)-PM) in patients with solid tumors. Ann Oncol 2010, 21:382-388.
14. Lehar J., Krueger A.S., Avery W., Heilbut A.M., Johansen L.M., Price E.R., et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 2009, 27:864.
15. Sun T.M., Wang Y.C., Wang F., Du J.Z., Mao C.Q., Sun C.Y., et al. Cancer stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds. Biomaterials 2014, 35:836-845.
16. Xiong M.H., Tang L.Y., Wang J. Synthesis and properties of diblock copolymers of poly (ethylene glycol) and poly (2-methoxyethyl ethylene phosphate) for enhanced paclitaxel solubility. Acta Polym Sin 2011, 853-860.
17. Paridaens R., Biganzoli L., Bruning P., Klijn J.G.M., Gamucci T., Houston S., et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. JClin Oncol 2000, 18:724-733.
18. Dombernowsky P., Gehl J., Boesgaard M., Jensen B.W., Ejlertsen B., Jensen T.P. Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Semin Oncol 1995, 22:13-17.
19. Bourgeois H., Ferru A., Lortholary A., Delozier T., Boisdron-Celle M., Abadie-Lacourtoisie S., et al. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer. Am J Clin Oncol 2006, 29:267-275.
20. Li M.Q., Song W.T., Tang Z.H., Lv S.X., Lin L., Sun H., et al. Nanoscaled poly(L-glutamic acid)/doxorubicin-amphiphile complex as pH-responsive drug delivery system for effective treatment of nonsmall cell lung cancer. ACS Appl Mater Interfaces 2013, 5:1781-1792.
21. Lv S., Li M., Tang Z., Song W., Sun H., Liu H., et al. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Acta Biomater 2013, 9:9330-9342.
22. Li M., Lv S., Tang Z., Song W., Yu H., Sun H., et al. Polypeptide/doxorubicin hydrochloride polymersomes prepared through organic solvent-free technique as a smart drug delivery platform. Macromol Biosci 2013, 13:1150-1162.
23. Ding J., Zhuang X., Xiao C., Cheng Y., Zhao L., He C., et al. Preparation of photo-cross-linked pH-responsive polypeptide nanogels as potential carriers for controlled drug delivery. JMater Chem 2011, 21:11383.
24. van Dijk-Wolthuis W.N.E., van de Water L., van de Wetering P., van Steenbergen M.J., Kettenes-van den Bosch J.J., Schuyl W.J.W., et al. Synthesis and characterization of poly-L-lysine with controlled low molecular weight. Macromol Chem Phys 1997, 198:3893-3906.
25. Kim S.K., Kim K., Lee S., Park K., Park J.H., Kwon I.C., et al. Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using a surface plasmon resonance. JPharm Biomed Anal 2005, 39:861-870.
26. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681.
27. Ding J.X., Chen J.J., Li D., Xiao C.S., Zhang J.C., He C.L., et al. Biocompatible reduction-responsive polypeptide micelles as nanocarriers for enhanced chemotherapy efficacy invitro. JMater Chem 2013, 1:69-81.
28. Chen S.D., Hu F.Z., Sheng R.L., Cao A.M. Preparation of new cholesterol-based amphiphilic liquid-crystalline diblock copolymers via raft approach and their thermal properties and self-assembly in mixed solutions. Acta Polym Sin 2013, 102-111.
29. Zhao C.L., Winnik M.A., Riess G., Croucher M.D. Fluorescence probe techniques used to study micelle formation in water-soluble block copolymers. Langmuir 1990, 6:514-516.
30. Du J.Z., Du X.J., Mao C.Q., Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. JAm Chem Soc 2011, 133:17560-17563.
31. Prabaharan M., Grailer J.J., Pilla S., Steeber D.A., Gong S.Q. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery. Biomaterials 2009, 30:5757-5766.
32. Bressenot A., Marchal S., Bezdetnaya L., Garrier J., Guillemin F., Plenat F. Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma. JHistochem Cytochem 2009, 57:289-300.